Esperion Theraptc (ESPR) Stock Price, Quote & News

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 734 887 3903

Website: www.esperion.com

Address:

3891 Ranchero Drive, Suite 150, Ann Arbor, United States

Lskynrd1 Feb. 23 at 12:53 PM

$ESPR Price Compression - validity dries up, candles get smaller, low volume, tight range,Stock coils like a spring. Smart lays in wait. Dead silence then BOOM BREAKOUT with volume and momentum

0 · Reply

CoreIntelligenceStudio Feb. 23 at 12:33 PM

$ESPR Pharmaceutical development company

0 · Reply

gbuster57 Feb. 23 at 12:03 PM

$ESPR

0 · Reply

Spooky22 Feb. 23 at 10:09 AM

$ESPR @That_Millionaire_Guy I have to admit, I pitty you and wonder, what made you such a sad guy, who posts on a board for a stock, which he clearly dislikes. I would rather use my time and energy for something, which brings joy to the world, but I guess thats just me ;-) I really wish you all the best 🙏 @OldManLogan I really appreciate your insights on several stocks :-) It helped me to make some clever decisions and was part of the reason, why I got nearly 100% return last year, thanks man 🫶

1 · Reply

Gregg617 Feb. 23 at 3:51 AM

$ESPR

0 · Reply

Albertowest Feb. 23 at 3:39 AM

$ESPR the amount of stupidity in your way of thinking is only matched by your laziness to at least try to sound like someone who has taken the time to learn English or use a spelling tool. I don’t know how would you expect us to take you seriously when you are that lazy. Your colleagues take the time to sound more professional and not like Tarzan, you could learn a thing or two from them.

0 · Reply

biotech_expert Feb. 23 at 3:01 AM

$ESPR

0 · Reply

Enjoyycall Feb. 23 at 2:58 AM

$ESPR 😳 This is a substantial difference: roughly 1 in 6 patients (16.7%) treated with bempedoic acid experienced a major cardiovascular event, compared to nearly 1 in 4.4 (22.8%) of those treated with ezetimibe. This means patients on bempedoic acid had a 27% lower relative risk of the composite major CV outcome compared to those on ezetimibe. Also, direct head-to-head trial data with these exact event rates isn’t widely published in major outcomes trials like CLEAR Outcomes, which compared bempedoic acid to placebo. BA 13–15% relative reduction overall. The figures here may come from a specific subgroup, modeling study, or indirect comparison such as predicted event avoidance when adding bempedoic acid versus ezetimibe alone in statin-treated patients. Physicians will take notice. Market should too.

0 · Reply

Hawaiianinvesta Feb. 23 at 2:45 AM

$ESPR 27% rrr is crazy good https://www.sciencedirect.com/science/article/abs/pii/S1933287426000474?dgcid=rss_sd_all

2 · Reply

OldManLogan Feb. 22 at 11:02 PM

$ESPR $10 to $15... Stocktwits ate my digits, lol.

0 · Reply

Esperion to Participate in The 2026 Citizens Life Sciences Conference

2026-02-17T15:02:27.000Z - 5 days ago

Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines

Tue, 17 Feb 2026 08:00:00 -0500 - 6 days ago

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

Wed, 11 Feb 2026 16:30:00 -0500 - 11 days ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2026-01-15T04:00:57.000Z - 5 weeks ago

Esperion Therapeutics Inc at JPMorgan Healthcare Conference Transcript

2026-01-15T00:35:58.000Z - 5 weeks ago

Esperion Therapeutics, Inc. (ESPR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-12T09:28:44.000Z - 6 weeks ago

Esperion Projects FY2025 U.S. Net Product Sales Growth Of 35% To 38%; Stock Up

Sun, 11 Jan 2026 18:00:00 -0500 - 6 weeks ago

Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Tue, 09 Dec 2025 16:30:00 -0500 - 2 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2025-11-25T17:58:24.000Z - 3 months ago

Esperion Therapeutics (ESPR) Set for Significant Growth with Cholesterol Drugs

2025-11-25T14:34:56.000Z - 3 months ago

Piper Sandler Initiates Coverage on Esperion Therapeutics (ESPR) | ESPR Stock News

2025-11-20T21:03:28.000Z - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript

2025-11-18T12:28:38.000Z - 3 months ago

Esperion Partner HLS Receives Health Canada Approval For NILEMDO To Lower LDL-Cholesterol

Tue, 18 Nov 2025 07:00:00 -0500 - 3 months ago

Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease

Wed, 12 Nov 2025 10:16:00 -0500 - 3 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

2025-11-12T02:33:28.000Z - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health - Slideshow

2025-11-12T02:31:31.000Z - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript

2025-11-11T07:06:28.000Z - 3 months ago

Esperion Therapeutics: Biotech With Limited Upside, Hold

2025-11-10T12:24:22.000Z - 3 months ago

Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability

Thu, 06 Nov 2025 16:30:00 -0500 - 3 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

2025-11-06T19:07:10.000Z - 3 months ago

Esperion outlines Vision 2040 and expects U.S. guideline inclusion in early 2026 while sustaining double-digit prescription growth

2025-11-06T19:06:45.000Z - 3 months ago

Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...

2025-11-06T19:06:17.000Z - 3 months ago

Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript

2025-11-06T18:20:56.000Z - 3 months ago

Q3 2025 Esperion Therapeutics Inc Earnings Call Transcript

2025-11-06T12:53:00.000Z - 3 months ago

Esperion Therapeutics Q3 2025 Earnings: Revenue Surpasses Estimates at $87. ...

2025-11-06T11:59:33.000Z - 3 months ago

Esperion Therapeutics (ESPR) Q3 Earnings: Mixed Results with Revenue Beat

2025-11-06T11:29:58.000Z - 3 months ago

Esperion Therapeutics (ESPR) Forecasts Profitability by Early 2026

Tue, 04 Nov 2025 08:00:00 -0500 - 3 months ago

Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

Mon, 27 Oct 2025 08:00:00 -0400 - 4 months ago

Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025

2025-10-08T12:01:10.000Z - 4 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Wed, 08 Oct 2025 08:01:10 -0400 - 4 months ago

Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

2025-10-08T06:59:11.000Z - 4 months ago

Esperion Therapeutics (ESPR) Announces $75M Stock Offering

2025-10-08T05:34:40.000Z - 4 months ago

Esperion Therapeutics prices $75M public offering

2025-10-08T05:24:49.000Z - 4 months ago

Esperion slides after pricing $75M stock offering

Tue, 07 Oct 2025 21:29:00 -0400 - 4 months ago

Esperion Announces Pricing of Public Offering of Common Stock

2025-10-07T22:02:53.000Z - 4 months ago

Esperion Therapeutics (ESPR) Launches Public Stock Offering

Tue, 07 Oct 2025 16:01:00 -0400 - 4 months ago

Esperion Announces Proposed Public Offering of Common Stock

2025-10-03T16:56:28.000Z - 5 months ago

Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's

Fri, 03 Oct 2025 08:00:00 -0400 - 5 months ago

Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040

Fri, 19 Sep 2025 08:00:00 -0400 - 5 months ago

Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

2025-09-08T02:17:50.000Z - 6 months ago

Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript

Fri, 05 Sep 2025 10:39:30 -0400 - 6 months ago

Top 2 Health Care Stocks That May Plunge This Month

Fri, 29 Aug 2025 08:00:00 -0400 - 6 months ago

Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

2025-08-14T10:31:00.000Z - 6 months ago

HLS Therapeutics Announces Q2 2025 Financial Results

Thu, 07 Aug 2025 17:30:00 -0400 - 7 months ago

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Tue, 05 Aug 2025 23:57:30 -0400 - 7 months ago

Esperion (ESPR) Q2 Revenue Jumps 12%

2025-08-05T14:11:07.000Z - 7 months ago

Esperion Therapeutics, Inc. 2025 Q2 - Results - Earnings Call Presentation

2025-08-05T14:10:29.000Z - 7 months ago

Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript

2025-08-05T10:01:18.000Z - 7 months ago

Esperion Therapeutics GAAP EPS of -$0.02 beats by $0.13, revenue of $82.39M beats by $19.34M

Tue, 05 Aug 2025 06:00:00 -0400 - 7 months ago

Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 22, 2025, 8:00 AM EDT - 7 months ago

Esperion to Report Second Quarter 2025 Financial Results on August 5

Jul 1, 2025, 8:06 AM EDT - 8 months ago

Esperion Appoints Craig Thompson to Board of Directors

Jun 14, 2025, 7:03 AM EDT - 9 months ago

Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?

May 12, 2025, 8:00 AM EDT - 10 months ago

Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

May 9, 2025, 8:00 AM EDT - 10 months ago

Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

May 8, 2025, 6:30 AM EDT - 10 months ago

Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada

May 6, 2025, 10:49 AM EDT - 10 months ago

Esperion Therapeutics, Inc. (ESPR) Q1 2025 Earnings Call Transcript

Apr 25, 2025, 8:00 AM EDT - 10 months ago

Esperion to Participate in The Citizens Life Sciences Conference

Apr 24, 2025, 8:00 AM EDT - 10 months ago

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Apr 10, 2025, 8:00 AM EDT - 11 months ago

Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors

Mar 4, 2025, 10:34 AM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 6:00 AM EST - 1 year ago

Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 8:00 AM EST - 1 year ago

Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

Feb 18, 2025, 8:00 AM EST - 1 year ago

Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

Dec 18, 2024, 7:00 AM EST - 1 year ago

Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

CRDF UI VOD DE FLNC GASS HII

Dec 13, 2024, 6:00 AM EST - 1 year ago

Esperion Announces $210 Million Convertible Debt Financing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel

Dec 8, 2024, 7:43 AM EST - 1 year ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Nov 18, 2024, 10:30 AM EST - 1 year ago

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Nov 13, 2024, 2:08 AM EST - 1 year ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 7, 2024, 1:35 PM EST - 1 year ago

Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 6:00 AM EST - 1 year ago

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 4, 2024, 8:00 AM EST - 1 year ago

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Oct 24, 2024, 8:00 AM EDT - 1 year ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

Sep 25, 2024, 4:30 PM EDT - 1 year ago

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Lskynrd1 Feb. 23 at 12:53 PM

$ESPR Price Compression - validity dries up, candles get smaller, low volume, tight range,Stock coils like a spring. Smart lays in wait. Dead silence then BOOM BREAKOUT with volume and momentum

0 · Reply

CoreIntelligenceStudio Feb. 23 at 12:33 PM

$ESPR Pharmaceutical development company

0 · Reply

gbuster57 Feb. 23 at 12:03 PM

$ESPR

0 · Reply

Spooky22 Feb. 23 at 10:09 AM

1 · Reply

Gregg617 Feb. 23 at 3:51 AM

$ESPR

0 · Reply

Albertowest Feb. 23 at 3:39 AM

0 · Reply

biotech_expert Feb. 23 at 3:01 AM

$ESPR

0 · Reply

Enjoyycall Feb. 23 at 2:58 AM

0 · Reply

Hawaiianinvesta Feb. 23 at 2:45 AM

$ESPR 27% rrr is crazy good https://www.sciencedirect.com/science/article/abs/pii/S1933287426000474?dgcid=rss_sd_all

2 · Reply

OldManLogan Feb. 22 at 11:02 PM

$ESPR $10 to $15... Stocktwits ate my digits, lol.

0 · Reply

BRLondon Feb. 22 at 10:30 PM

$ESPR at least it's not Iran tensions this time lol hope you get your re-entry soon and stop coming up with BS. Every message negative since you sold but you can't wait to get back in

2 · Reply

OldManLogan Feb. 22 at 10:06 PM

$ESPR There were over 10 million Zetia scripts written last year in the US, but sure Esperion would only go to $5 on news like that, lmao. (Try $1 -$1 .) And you wonder why @Albertowest and @omar_progressivetrading call you out for being a soft FUDster 😅😂🤣

3 · Reply

YoloAlfred Feb. 22 at 9:31 PM

$DNLI $ETON $VNDA $ESPR

0 · Reply

BullDonald Feb. 22 at 9:05 PM

$DNLI Love it 🚀 $ETON Love it 🚀 $VNDA Love it too Much 🚀 $ESPR 👈 still trash with a CULT like board.

0 · Reply

Rustyton Feb. 22 at 8:25 PM

$ESPR it’s always been a combo of inflammation and ldl-c… BA should be the go to statin alternative and add-on.

0 · Reply

simbha Feb. 22 at 8:24 PM

$ESPR. Contrarian view: Fair chance to be back to $3 after the Earnings call. They did a nice reset on over sold conditions but weekly is not healthy yet and I will wait for next opportunity in this swing. Earnings call day will give enough trend of direction.

1 · Reply

Dave_100 Feb. 22 at 8:01 PM

$ESPR I hope this was available to the group tha worked on this guidelines update.

1 · Reply

cert Feb. 22 at 6:52 PM

$ESPR

0 · Reply

cert Feb. 22 at 6:49 PM

$ESPR

2 · Reply

MiamiBeachDog Feb. 22 at 6:20 PM

$ESPR https://x.com/MACROVET888/status/2025592556516511839?s=20

2 · Reply

Fish2day Feb. 22 at 4:55 PM

$ESPR USA, nice win for us in hockey game, bring some gold to ESPR now that OPEX is done until next month. News abound so things will get interesting.

1 · Reply

YoloAlfred Feb. 22 at 4:36 PM

$ESPR 😎😎😎😎😎$VNDA😎😎😎😎😎😎

0 · Reply

Market Cap	831.94M
Revenue (ttm)	332.31M
Net Income (ttm)	-51.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	19.77
Profit Margin	-15.57%
Debt to Equity Ratio	-0.34

Volume	2,469,800
Avg Vol	4,908,648
Day's Range	N/A - N/A
Shares Out	239.06M
Stochastic %K	52%
Beta	1.09
Analysts	Strong Sell
Price Target	$6.46